Clinical trialCLINICALTRIALSApr 1
Researchers are testing a combination of two cancer drugs called dabrafenib and trametinib in patients with rare tumors that have a specific genetic change called BRAF V600E. This is a phase IV study, which means the drugs have already been approved and doctors are gathering more information about how well they work. The study will include children (age 1 and up) and adults, and is currently looking for 40 patients to participate.
WHY IT MATTERSIf you have a rare solid tumor with a BRAF V600E mutation and your doctor has already recommended dabrafenib plus trametinib treatment, this trial offers an opportunity to participate in research that could help future patients while receiving the same treatment your doctor planned for you anyway.
Clinical trialCLINICALTRIALSApr 1
This is a continuation study for patients who are already taking the cancer drugs dabrafenib and/or trametinib and have done well on them. If your doctor thinks you're still benefiting from these medications after your original trial ends, you may be able to keep taking them through this new study. The study is looking for about 100 patients with various types of cancer including melanoma, lung cancer, and brain tumors.
WHY IT MATTERSThis rollover study allows patients whose cancers are responding well to dabrafenib and/or trametinib to continue access to these drugs after their original trial ends, rather than losing treatment.
ResearchPUBMEDApr 1
Researchers studied whether the amount of cancer in a patient's body before treatment affects how well two immunotherapy drugs work together. They looked at 722 patients with rare cancers who received nivolumab and ipilimumab (two drugs that help the immune system fight cancer). The study wanted to understand if patients with smaller tumors do better than those with larger tumors when treated with these combination drugs.
WHY IT MATTERSIf baseline tumor size predicts treatment response in rare cancers, doctors could better counsel patients on expected outcomes and identify which patients might benefit most from this dual immunotherapy approach before starting treatment.
PolicyPUBMEDApr 1
Researchers compared how quickly rare disease drugs become available in China versus the United States between 2001 and 2024. The study looked at a problem called 'drug loss' — when medicines are approved in the US but never reach Chinese patients — and 'drug lag' — when there's a long delay before Chinese approval. The findings help the Chinese government understand what's blocking patients from getting treatments that already exist elsewhere in the world.
WHY IT MATTERSIf you have a rare disease in China, this research directly impacts whether you can access treatments that may already be approved and available in the United States, potentially identifying barriers your doctor or patient advocacy groups can help address.